Novo Nordisk's Promising Obesity Drug Aims for 25% Weight Loss
Novo Nordisk has announced that its experimental obesity drug, CagriSema, is showing side effects similar to existing GLP-1 drugs. The company expects the new drug to deliver a 25% weight loss. Novo Nordisk anticipates releasing data from a late-stage trial by the end of 2024.
- Country:
- United Kingdom
Novo Nordisk's latest experimental drug, CagriSema, has shown promise in trials, exhibiting side effects similar to those of existing GLP-1 drugs. The company maintains that this new injection could achieve an unprecedented 25% weight loss.
In an interview with Reuters, Martin Holst Lange, head of development at Novo Nordisk, disclosed these developments as the company released its third-quarter financial results, which surpassed forecasts.
Data from a late-stage trial of CagriSema—a two-drug combination obesity treatment similar to Novo Nordisk's popular Wegovy injection—is expected to be available by the close of 2024.
(With inputs from agencies.)
Advertisement
ALSO READ
From Trials to Triumph: The Inspiring Journey of 'Cancelled to Crowned'
French Rugby: A Year of Trials and Triumphs
Glenn Maxwell's IPL Odyssey: Triumphs, Trials, and Transformations
Allahabad High Court Demands Swift Action on Lingering Lawmaker Trials
Trump's Crusade: Political Trials and Election Intrigues